Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233462 | 0.92 | PPARD (0.51) | PPARDPPARAPPARG | |
| SCHEMBL27233332 | 0.91 | PPARD (0.47) | PPARDPPARAPPARGESR1 | |
| SCHEMBL27233431 | 0.91 | PPARD (0.47) | PPARDPPARAPPARGESR1KDM4E | |
| SCHEMBL27233451 | 0.91 | PPARD (0.47) | PPARDPPARAPPARGESR1KDM4E | |
| SCHEMBL27233400 | 0.91 | PPARD (0.49) | PPARDPPARAPPARGESR1 | |
| SCHEMBL27233336 | 0.89 | PPARD (0.47) | PPARDPPARAPPARGKDM4ETP53 | |
| SCHEMBL27233333 | 0.89 | PPARD (0.60) | PPARDPPARAPPARG | |
| SCHEMBL27233470 | 0.87 | PPARD (0.43) | PPARDPPARAPPARGESR1KDM4E | |
| SCHEMBL27233412 | 0.87 | PPARD (0.58) | PPARDPPARAPPARG | |
| SCHEMBL27233458 | 0.84 | PPARD (0.42) | PPARDPPARAPPARGKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| EP-4378931-A1 | TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF | Harbin Medisan Pharmaceutical Co., LTD. (CN) | 2024-06-05 | — | — | EP | claimed |
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4378931-A1 | TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF | Harbin Medisan Pharmaceutical Co., LTD. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-114853686-B | Triazolone compound and medical application thereof | 中国药科大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-114853686-A | Triazole ketone compound and medical application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188044-A1 | TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.